Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR925916ApriorityCriticalpatent/FR3024M/fr
Application filed by Roussel Uclaf SAfiledCriticalRoussel Uclaf SA
Priority to FR940550Aprioritypatent/FR2868M/fr
Priority to GB6965/64Aprioritypatent/GB1026928A/en
Priority to US346107Aprioritypatent/US3314979A/en
Priority to DE19641468863prioritypatent/DE1468863A1/de
Priority to NL6401757Aprioritypatent/NL6401757A/xx
Priority to CH230964Aprioritypatent/CH414596A/fr
Application grantedgrantedCritical
Publication of FR2868MpublicationCriticalpatent/FR2868M/fr
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/16—Amides, e.g. hydroxamic acids
A61K31/18—Sulfonamides
Landscapes
Health & Medical Sciences
(AREA)
Chemical & Material Sciences
(AREA)
Medicinal Chemistry
(AREA)
Pharmacology & Pharmacy
(AREA)
Epidemiology
(AREA)
Life Sciences & Earth Sciences
(AREA)
Animal Behavior & Ethology
(AREA)
General Health & Medical Sciences
(AREA)
Public Health
(AREA)
Veterinary Medicine
(AREA)
FR940550A1963-02-251963-07-05Nouveau médicament notamment pour le traitement du diabete calcique et des troubles du métabolisme du calcium.
ActiveFR2868M
(fr)
Nouveau médicament, notamment pour le traitement des troubles de l'anabolisme protidique, des manifestations de l'hypoandrogénie et de l'hyperfolliculine.